Analytical Data
-
Gene name
gp210
- Application
-
Alternative Names
gp210；KIAA0906；Nuclear pore membrane glycoProtein 210
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TEM1
-
Expression Region
28-238aa
-
AA Sequence
LNIPKVLLPFTRATRVNFTLEASEGCYRWLSTRPEVASIEPLGLDEQQCSQKAVVQARLTQPARLTSIIFAEDITTGQVLRCDAIVDLIHDIQIVSTTRELYLEDSPLELKIQALDSEGNTFSTLAGLVFEWTIVKDSEADRFSDSHNALRILTFLESTYIPPSYISEMEKAAKQGDTILVSGMKTGSSKLKARIQEAVYKNVRPAEVRLL
-
Molecular Weight
27.6kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GP210 is a protein that plays a crucial role in the formation and function of hepatic bile canaliculi, and it is encoded by the gene that is essential for normal liver development. Research on GP210 has gained significant attention due to its association with various liver diseases, particularly those related to cholestasis, such as progressive familial intrahepatic cholestasis (PFIC) and primary biliary cholangitis (PBC). Mutations in the GP210 gene can disrupt bile transport, leading to impaired bile flow and subsequent liver damage. Understanding the structure and function of GP210 can provide insights into the molecular mechanisms underlying these diseases and facilitate the development of targeted therapies. Additionally, GP210 has potential as a biomarker for liver diseases, making it relevant for diagnostic purposes. Recent advances in recombinant protein technology have enabled the production of GP210 in laboratory settings, allowing researchers to investigate its characteristics and interactions in detail. This research is pivotal for identifying therapeutic targets and designing novel treatment strategies for liver diseases involving bile duct abnormalities. As a result, GP210 recombinant protein studies are crucial for better understanding liver pathology and improving patient outcomes in liver-related disorders.
